Anaplastic large cell lymphoma as a posttransplant lymphoproliferative disorder in a renal transplant patient: A case report.


Journal

EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 10 03 2020
revised: 23 04 2020
accepted: 23 04 2020
entrez: 18 7 2022
pubmed: 10 7 2020
medline: 10 7 2020
Statut: epublish

Résumé

We report a case of a 45-year-old female who developed an ALK-positive anaplastic large cell lymphoma (ALCL) 9 years after renal transplant. The patient underwent a cadaveric renal transplant for diabetic nephropathy, and presented 9 years later with fever and multiorgan dysfunction. The initial CT scans showed multiple enlarged supra- and infradiaphrgamatic lymph nodes. A CT-guided core needle biopsy of a retroperitoneal lymph node revealed ALK positive ALCL. She received six cycles of cyclophosphamide, adriamycin, vincristine, etoposide, and prednisone, and has been in remission for over 3 years. Monomorphic T-cell posttransplant lymphoproliferative disorder (PTLD) is an established but rare entity of PTLD and generally carries poor prognosis. This is a case report of a late PTLD with pathology reporting an aggressive T-cell lymphoma that has been successfully treated with multiagent chemotherapy.

Identifiants

pubmed: 35847710
doi: 10.1002/jha2.13
pii: JHA213
pmc: PMC9175764
doi:

Types de publication

Journal Article

Langues

eng

Pagination

364-367

Informations de copyright

© 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.

Déclaration de conflit d'intérêts

The authors declare that there is no conflict of interest.

Références

Saudi J Kidney Dis Transpl. 2009 Jul;20(4):646-51
pubmed: 19587509
Blood. 2015 May 7;125(19):2908-14
pubmed: 25758828
J Cutan Pathol. 2007 Dec;34 Suppl 1:1-8
pubmed: 17997729
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Lancet. 2019 Jan 19;393(10168):229-240
pubmed: 30522922
Blood. 2015 Nov 12;126(20):2274-83
pubmed: 26384356
Cancer Treat Res. 2015;165:305-27
pubmed: 25655616
J Clin Oncol. 2013 Apr 1;31(10):1302-9
pubmed: 23423742
Oncotarget. 2017 Jun 30;8(57):96903-96912
pubmed: 29228580

Auteurs

Manar Alabdulbaqi (M)

Department of Hematology The Ottawa Hospital Ottawa Ontario Canada.

Melissa Toupin (M)

Department of Hematology Ottawa Hospital General Campus Ottawa Ontario Canada.

Philip Berardi (P)

Department of Anatomic Pathology/Hematopathology Ottawa Hospital General Campus Ottawa Ontario Canada.

Arleigh McCurdy (A)

Department of Hematology University of Ottawa Ottawa Ontario Canada.

Classifications MeSH